Loading

Avstera Therapeutics Corp.

June 04, 2024
Company Presentation
Oncology
Company Presentation Theater 1
Avstera Therapeutics is an oncology-focused biotech company headquartered in the Philadelphia area dedicated to address the large disease burden and significant unmet need of advanced cancer patients. With a focus on foundational tumor biology science, Avstera leverages cutting edge approaches to tackle key immunological challenges seen in the tumor microenvironment, such as the modulation of immunosuppressive macrophages. Avstera's lead program is an orally bioavailable, highly selective HDAC6i which is in Phase I.
Avstera Therapeutics Corp.
Company Website: http://www.avstera.com
Lead Product in Development: AVS100 - Highly Selective Oral HDAC6 Inhibitor Targeting Locally Advanced or Metastatic Solid Tumors
Number Of Unlicensed Products (For Which You Are Seeking Partners): 3

Company HQ City

Malvern

Company HQ State

PA

Company HQ Country

United States

CEO/Top Company Official

Karthik Musunuri

Development Phase of Primary Product

Phase I
Speakers
Karthik Musunuri, BS
CEO & Co-Founder
Avstera Therapeutics Corp.
Back to Session List

BIO DOUBLE HELIX SPONSOR

Our sponsors help support BIO's mission to support and advocate for the biotechnology industry.

Loading

BIO HELIX SPONSORS